Our core business is helping more people complete treatment — an access-to-medicine mission mapped to the UN Sustainable Development Goals.
Digitized workflows cut paper and travel — the patient programme management platform converts over 60,000 services to electronic form each year — while GHG inventories establish a year-on-year decarbonization baseline.
Improving access, easing financial toxicity; direct subsidies to cancer and rare-disease patients via the charitable trust.
Group sustainability, governance and GHG-inventory disclosures are published here on the group's corporate site.
Sustainability performance is rated and audited by independent third parties, evidencing the group's disclosures.
Bronze medal in the EcoVadis sustainability rating (2025 assessment year) — within the top 35% of companies assessed that year — covering environment, labour and human rights, ethics and sustainable procurement.
Joined the SBTi SME 2030 Net-Zero initiative, with reduction targets approved by the Science Based Targets initiative under its streamlined SME validation route: net-zero by 2030, cutting scope 1+2+3 emissions 100% from a 2023 base year, with scope 1 and 2 aligned to a 1.5°C pathway. The SBTi is a joint initiative of CDP, the UN Global Compact, the World Resources Institute and WWF.
Quality, information-security and privacy information management systems, all SGS-audited, covering patient assistance and support programme (PAP/PSP) services, systems and data protection.
Aligned to the Pharmaceutical Supply Chain Initiative principles for ethics, labour, health, safety, environment and management systems.
iHelp Charitable Trust Fund
Funded by donations from companies, organizations and individuals, the trust provides emergency-relief subsidies for cancer and rare-disease patients — helping them face treatment and return to life.